Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

@article{GarciaManero2005FinalRO,
  title={Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.},
  author={Guillermo Garcia-Manero and H Yang and Blanca S{\'a}nchez-Gonz{\'a}lez and Srdan Verstovsek and Alessandra Ferrajoli and Michael J. Keating and Michael Andreeff and Susan P. O’BRIEN and J Cortes and William G Wierda and Stefan Faderl and Charles Koller and Jan R Davis and Gail Morris and Jean-Pierre Issa and Stanley R Frankel and Victoria M. Richon and Bernard M. Fine and Hagop M. Kantarjian},
  journal={Blood},
  year={2005},
  volume={106},
  pages={2801-2801}
}

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat

Biologics : targets & therapy • 2007
View 4 Excerpts
Highly Influenced

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology • 2008
View 3 Excerpts